Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
Atopic dermatitis (AD) causes people to be susceptible to skin infection and inflammations. The purpose of this study is to determine the immune response to chicken pox vaccine in children with or without AD who received the vaccine 2 to 16 weeks prior to the study visit.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)|
- Cell-mediated immune responses as assessed by measurement of numbers of VZV specific T cells. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- To determine if children with AD have VZV-specific humoral responses to varicella vaccination that differ from those of nonatopic controls. [ Time Frame: 36 months ] [ Designated as safety issue: No ]
Biospecimen Retention: None Retained
Blood collected for endpoint measurements.
|Study Start Date:||December 2005|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
Participants with AD
Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
AD is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Children with AD given the smallpox vaccine could develop a life-threatening condition known as eczema vaccinatum. This immune response is not currently understood. The purpose of this study is to understand the immune response to a viral vaccine in children with AD. This will be accomplished by studying immune response to the chicken pox vaccine in children with AD in comparison to those without AD.
This study will consist of one study visit occurring about 2 to 16 weeks after the child received the chicken pox vaccination. During this visit, physical and skin exams will occur. Personal and family medical histories and blood collection will also occur. The chicken pox vaccine will not be given as a part of this study. Subjects will receive the results of radioallergosorbent (RAST) testing that will tell if they are allergic to some common items (e.g., mold, grass).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00406081
|United States, Colorado|
|National Jewish Health|
|Denver, Colorado, United States, 80206|
|United States, Massachusetts|
|Children's Hospital Boston|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Lynda Schneider, MD||Children's Hospital Boston|
|Principal Investigator:||Donald Y. Leung, MD, PhD||National Jewish Health|